期刊
PHARMACOGENOMICS
卷 16, 期 4, 页码 361-372出版社
FUTURE MEDICINE LTD
DOI: 10.2217/PGS.14.179
关键词
anthracyclines; cardiotoxicity; clinical trial; heart failure; RICOVER-60; SNP
资金
- NGFN2 of the German Federal Ministry for Education and Science [01GS0421]
- Deutsche Forschungsgemeinschaft [WO505/3-1]
- Deutsche Krebshilfe [109756]
Aim: To identify gene variants responsible for anthracycline-induced cardiotoxicity. Patients & methods: Polymorphisms of the NADPH oxidase subunits and of the anthracycline transporters ABCC1, ABCC2 and SLC28A3 were genotyped in elderly patients (61-80 years) treated for aggressive CD20(+) B-cell lymphomas with CHOP-14 with or without rituximab and followed up for 3 years. Results: The accumulation of RAC2 subunit genotypes TA/AA among cases was statistically significant upon adjustment for gender, age and doxorubicin dose in a multivariate logistic regression analysis (OR: 2.3, p = 0.028; univariate: OR: 1.8, p = 0.077). RAC2 and CYBA genotypes were significantly associated with anthracycline-induced cardiotoxicity in a meta-analysis of this and a similar previous study. Conclusion: Our results support the theory that NADPH oxidase is involved in anthracycline-induced cardiotoxicity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据